Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch

Candel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer patients, has signed a commercialization agreement with EVERSANA, a global commercialization services provider, to gear up for the potential US launch of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk, localized prostate cancer. Under the deal, EVERSANA will deliver an integrated range of services covering data and analytics, medical affairs, market access, and field operations.